Immunic Touts Positive Vidofludimus Calcium Data In Multiple Sclerosis Candidate

  • Immunic Inc IMUX has reported newly available data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS). 
  • During the 24-week treatment period, 12-week and 24-week Confirmed Disability Worsening (12w/24wCDW) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. 
  • Related: Immunic's Early Cut Data From Psoriasis Candidate Failed To Show Desired Activity Signal Over Placebo.
  • In the open-label extension (OLE) phase, the proportion of patients free from 12wCDW was 97.6% after 48 weeks and 94.5% after 96 weeks of vidofludimus calcium treatment.
  • Similar results were observed for 24wCDW and sustained CDW. The OLE phase also showed low relapse activity.
  • Long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening over time and compares favorably to historical trial data for currently available multiple sclerosis medications.
  • Price Action: IMUX shares are up 9.22% at $1.55 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!